Buprenorphine, as the main ingrdient of Suboxone, was first marketed in the 1980s in the US, as an opioid pain reliever. For this purpose, it was marketed in its pure form (without naloxone as found in Suboxone) as as Temgesic sublingual tablets, and also an injectible form. In October 2002, the Food and Drug Administration (FDA) of the United States, and Health Canada in 2008 approved Suboxone, buprenorphine's higher-dose sublingual tablet preparations indicated for detoxification and long-term maintenance therapy in opioid dependency.
In addition to the sublingual tablet, Suboxone is now marketed in the US form of a sublingual film. The film is not available in Canada yet.